<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>LA011290-0185</title>
	</head>
	<body>
		<main>
			<p><P> January 12, 1990, Friday, P.M. Final  </P> <P> P. M. BRIEFING;  </P> <P> 2 COMPANIES FINED $400,000 IN GENERIC DRUG PAYOFF SCANDAL  </P> <P> A federal judge fined Par Pharmaceutical Inc. and its Quad Pharmaceuticals unit  a total of $400,000 today for their role in a Food and Drug Administration  payoff scandal involving generic drugs.  </P> <P> Par was fined $150,000 and Quad $250,000 in a proceeding before U.S. District  Judge John Hargrove.  </P> <P> Par and Quad faced maximum fines of $500,000 each after agreeing to plead  guilty to criminal charges stemming from a nearly two-year government probe of  the generic drug industry and its regulation by the FDA.  </P> <P> In July, federal prosecutors had charged that Par and Quad executives gave cash  payoffs to an FDA chemist when the chemist was reviewing the companies' drug  applications.  </P> <P> Par, based in Spring Valley, N.Y., remains the focus of a separate criminal  investigation being pursued by the U.S. Justice Department.  </P> <P> The staff of the House Energy and Commerce Committee's investigations  subcommittee disclosed in September that Par was under Justice Department  investigation.  </P> <P> The subcommittee staff said in a memo that Par's drug development process was  found to be "rife with problems such as material false statements, systematic  destruction of unfavorable test results . . . and material alterations in  chemical formulations between . . . tested and marketed products."  </P></p>
		</main>
</body></html>
            